Missing content? – Request curation!
Request curation for specific Genes, variants, or PubMed publications.
Have questions, comments or suggestions? - Let us know!
Email us at : email@example.com
|Therapy Name||Capmatinib + Gefitinib|
|Drug Name||Trade Name||Synonyms||Drug Classes||Drug Description|
|Capmatinib||Tabrecta||INC280|INC-280|INCB028060|INCB28060|INCB 28060||MET Inhibitor 51||Tabrecta (capmatinib) inhibits MET signaling and may induce cell death in tumors overexpressing MET or expressing constitutively activated MET (PMID: 31853265). Tabrecta (capmatinib) is FDA approved for use in patients with metastatic non-small cell lung cancer harboring MET exon 14 skipping mutations (FDA.gov).|
|Gefitinib||Iressa||ZD1839||EGFR Inhibitor (Pan) 47 EGFR Inhibitor 1st gen 3||Iressa (gefitinib) is a first-generation EGFR inhibitor that binds EGFR and inhibits downstream signaling, potentially resulting in decreased growth of tumors with EGFR activation (PMID: 26980062, PMID: 25302162, PMID: 15284455). Iressa (gefitinib) is FDA approved for use in patients with non-small cell lung cancer harboring an EGFR exon 19 deletion or EGFR L858R (FDA.gov).|
|Molecular Profile||Indication/Tumor Type||Response Type||Therapy Name||Approval Status||Evidence Type||Efficacy Evidence||References|
|Clinical Trial||Phase||Therapies||Title||Recruitment Status|
|NCT03040973||Phase II||Capmatinib + Nazartinib Capmatinib Capmatinib + Gefitinib||Study to Allow Patients Previously Participating in a Novartis Sponsored Trial to Continue Receiving INC280 Treatment as Single Agent or in Combination With Other Treatments.||Recruiting|